It has been 100 years since insulin was discovered. Insulin therapy remains the cornerstone for the management of diabetes. Advances in human physiology, pathology, molecular biology, biotechnology, biomedical engineering and devices have added tremendously to the journey of one of the greatest discoveries of modern medicine. Epidemiology of diabetes has gone through a major shift in a century; many oral drugs have been introduced for the management of type 2 diabetes; glucose monitoring has also gone through a sea change with the availability of novel parameters like continuous glucose monitoring, as has insulin delivery, with the availability of insulin pumps and the artificial pancreas. In this article, we look into historical facts, challenges, limitations and future developments of insulin therapy.
HegeleRAMaltmanGM. Insulin’s centenary: the birth of an idea. Lancet Diabetes Endocrinol2020; 8: 971–77.
2.
GaleEA. The rise of childhood type 1 diabetes in the 20th century. Diabetes2002; 51: 3353–61.
3.
RubinoFAmielSAZimmetP, et al. New-onset diabetes in COVID-19. New Engl J Med2020; 383: 789–90.
4.
FralickMZinmanB. The discovery of insulin in Toronto: beginning a 100 year journey of research and clinical achievement. Diabetologia2021; 64: 947–53.
5.
BantingFGBestCHCollipJB, et al. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J1922; 12: 141–46.
6.
GrunbergerG. The need for better insulin therapy. Diabetes Obes Metab2013; 15: 1–5.
7.
PetersonGE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin2006; 22: 2613–19.
8.
DevriesJHNattrassMPieberTR. Refining basal insulin therapy: what have we learned in the age of analogues?Diabetes Metab Res Rev2007; 23: 441–54.
9.
HaahrHHeiseT. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet2014; 53: 787–800.
10.
RatnerREGoughSCMathieuC, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab2013; 15: 175–84.
11.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes – 2020. Diabetes Care2020; 43: S98–S110.
WooVBerardLRoscoeR. Understanding the clinical profile of insulin degludec, the latest basal insulin approved for use in Canada: a narrative review. Diabetes Ther2020; 11: 2539–53.
14.
Del PratoS. How conclusive is the CONCLUDE trial?Diabetologia2020; 63: 692–97.
15.
RichterBNeisesG. Human insulin versus animal insulin in people with diabetes mellitus. Cochrane Database Syst Rev2003; 3: CD003816.
16.
MohanV. Why are Indian diabetic subjects more prone to coronary artery disease?Int J Diabetes Dev Countries2004; 24: 1–6.
17.
HollemanFHoekstraJB. Insulin lispro. N Engl J Med1997; 337: 176–83.
18.
ChapmanTMNobleSGoaKL. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs2002; 62: 1945–81.
19.
BeckerRHFrickADBurgerF, et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes2005; 113: 435–43.
20.
ChaplinS. Fiasp: a new faster-acting insulin aspart formulation for diabetes. Prescriber2017; 28(7): 37–8.
21.
GrunbergerGBhargavaALyT, et al. Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: the VIVID study. Diabetes Obes Metab2020; 22: 434–41.
22.
BarnettAH. Exubera inhaled insulin: a review. Int J Clin Pract2004; 58: 394–401.
23.
HeinemannL. The failure of exubera: are we beating a dead horse?J Diabetes Sci Technol2008; 2: 518–29.
24.
GoldbergTWongE. Afrezza (insulin human) inhalation powder: a new inhaled insulin for the management of type-1 or type-2 diabetes mellitus. PT2015; 40: 735–41.
25.
JudeEBTrescoliCEmralR, et al. Effectiveness of premixed insulin to achieve glycaemic control in type 2 diabetes: a retrospective UK cohort study. Diabetes Obesty Metab2021; 23: 929–37.
26.
DemirTTuranSUnluhizarciK, et al. Use of insulin degludec/insulin aspart in the management of diabetes mellitus: expert panel recommendations on appropriate practice patterns. Front Endocrinol (Lausanne)2021; 12: 616514.
27.
BuseJBVilsbøllTThurmanJ, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care2014; 37: 2926–33.
28.
RosenstockJBajajHSJanežA, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med2020; 383: 2107–16.
29.
HovelmannUBrondstedLKristensenNR, et al. Insulin icodec: an insulin analog suited for once-weekly dosing in type 2 diabetes. Abstract 237-OR. Presented at the 80th Scientific Sessions of the American Diabetes Association, 14 June, 2020.
30.
HeiseTChienJBealsJ, et al. Basal Insulin Fc (BIF), a novel insulin suited for once weekly dosing for the treatment of patients with diabetes mellitus. J Endocr Soc2021; 5: A329.
31.
FarmerTDJenkinsECO’BrienTP, et al. Comparison of the physiological relevance of systemic vs. Portal insulin delivery to evaluate whole body glucose flux during an insulin clamp. Am J Physiol Endocrinol Metab2015; 308: E206–22.
32.
JacoberSJPrinceMJBealsJM, et al. Basal insulin peglispro: overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action. Diabetes Obes Metab2016; 18: 3–16.
33.
BodeBWWeinstockRSGargSK, et al. 111-LB: hepatic insulin delivery to minimize hypoglycemic events in persons with type 1 diabetes: the OPTI-1 study. Diabetes2020; 69: 111–LB.
34.
HarrisonGA. Insulin in alcoholic solution by the mouth. Br Med J1923; 2: 1204–5.
35.
KhedkarALebovitzHFlemingA, et al. Pharmacokinetics and pharmacodynamics of insulin tregopil in relation to premeal dosing time, between meal interval, and meal composition in patients with type 2 diabetes mellitus. Clin Pharmacol Drug Dev2020; 9: 74–86.
KjeldsenTBHubálekFTagmoseTM, et al. Engineering of orally available, ultralong-acting insulin analogues: discovery of OI338 and OI320. J Med Chem2021; 64: 616–28.
38.
VeisehOLangerR. A smart insulin patch. Nature2015; 524: 39–40.
39.
HeiseT. The future of insulin therapy. Diabetes Res Clin Pract2021; 175: 108820.
